Literature DB >> 22886478

Is there 'progression through grade' in ductal invasive breast cancer?

Barbara Schymik1, Horst Buerger, Annika Krämer, Ulli Voss, Petra van der Groep, Wolfgang Meinerz, Paul J van Diest, Eberhard Korsching.   

Abstract

Recent molecular data pointed towards the possibility of a stepwise dedifferentiation in a subgroup of invasive breast cancer (BC) cases. It was hypothesized that oestrogen receptor positive (ER+) grade 3 (G3) ductal invasive BCs are the end stage of a dedifferentiation process of luminal BC. A progression of luminal A towards luminal B BCs associated with a 'progression through grade' and an increased cell proliferation seemed the obvious explanation. In order to verify this hypothesis on a morphological and immunohistochemical level, we investigated 865 invasive BC cases. All cases were reviewed for the presence of intratumoural heterogeneity in grade of the invasive cancer and the presence of associated ductal carcinoma in situ (DCIS). With the use of tissue microarrays, the molecular subtype was determined and correlated with clinico-pathological features. In addition, all cases were stained for p21, p27, Ki-67, Cyclin D1, bcl-2, p53, and p16 and the results subjected to a biomathematical dependency analysis. The frequency of ER-positivity decreased with tumour size. The frequency of luminal A BC decreased as well, whereas the number of luminal B BCs remained constant. A gradual increase of the frequency of basal-like, HER2-driven and non-expressor BCs with tumour size was seen. In only 1 out of 865 BC cases, both a G1 and a G3 invasive cancer component was seen within the same BC. In two cases, a ductal invasive G1 carcinoma was associated with a poorly-differentiated DCIS. The frequency of columnar cell lesions was evenly distributed over ER+ and ER- ductal invasive G3 carcinomas. The biomathematical analysis gave striking hints against an obligate progression of BC trough grade. In conclusion, our results show that a morphological recognizable striking 'progression through grade' at least in its extreme form from G1 towards G3 is a very rare event in the natural course of invasive BC, including luminal BC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22886478     DOI: 10.1007/s10549-012-2195-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Biofunctional characteristics of in situ and invasive breast carcinoma.

Authors:  Sara Bravaccini; Anna Maria Granato; Laura Medri; Flavia Foca; Fabio Falcini; Wainer Zoli; Monica Ricci; Giuseppe Lanzanova; Nestory Masalu; Luigi Serra; Federico Buggi; Secondo Folli; Rosella Silvestrini; Dino Amadori
Journal:  Cell Oncol (Dordr)       Date:  2013-06-27       Impact factor: 6.730

2.  Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation.

Authors:  Hirotaka Kanzaki; Nishit K Mukhopadhya; Xiaojiang Cui; V Krishnan Ramanujan; Ramachandran Murali
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2016-01-21

3.  Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study.

Authors:  Joseph D Butner; Prashant Dogra; Caroline Chung; Javier Ruiz-Ramírez; Sara Nizzero; Marija Plodinec; Xiaoxian Li; Ping-Ying Pan; Shu-Hsia Chen; Vittorio Cristini; Bulent Ozpolat; George A Calin; Zhihui Wang
Journal:  Cell Death Dis       Date:  2022-05-21       Impact factor: 9.685

4.  TMAinspiration: Decode Interdependencies in Multifactorial Tissue Microarray Data.

Authors:  Florian Boecker; Horst Buerger; Nikhil V Mallela; Eberhard Korsching
Journal:  Cancer Inform       Date:  2016-06-29

5.  Site-specific gene expression patterns in oral cancer.

Authors:  Gesche Frohwitter; Horst Buerger; Eberhard Korsching; Paul J van Diest; Johannes Kleinheinz; Thomas Fillies
Journal:  Head Face Med       Date:  2017-05-10       Impact factor: 2.151

Review 6.  The potential of liquid biopsies for the early detection of cancer.

Authors:  Ellen Heitzer; Samantha Perakis; Jochen B Geigl; Michael R Speicher
Journal:  NPJ Precis Oncol       Date:  2017-10-17

7.  Common variants in breast cancer risk loci predispose to distinct tumor subtypes.

Authors:  Thomas U Ahearn; Haoyu Zhang; Montserrat García-Closas; Nilanjan Chatterjee; Kyriaki Michailidou; Roger L Milne; Manjeet K Bolla; Joe Dennis; Alison M Dunning; Michael Lush; Qin Wang; Irene L Andrulis; Hoda Anton-Culver; Volker Arndt; Kristan J Aronson; Paul L Auer; Annelie Augustinsson; Adinda Baten; Heiko Becher; Sabine Behrens; Javier Benitez; Marina Bermisheva; Carl Blomqvist; Stig E Bojesen; Bernardo Bonanni; Anne-Lise Børresen-Dale; Hiltrud Brauch; Hermann Brenner; Angela Brooks-Wilson; Thomas Brüning; Barbara Burwinkel; Saundra S Buys; Federico Canzian; Jose E Castelao; Jenny Chang-Claude; Stephen J Chanock; Georgia Chenevix-Trench; Christine L Clarke; J Margriet Collée; Angela Cox; Simon S Cross; Kamila Czene; Mary B Daly; Peter Devilee; Thilo Dörk; Miriam Dwek; Diana M Eccles; D Gareth Evans; Peter A Fasching; Jonine Figueroa; Giuseppe Floris; Manuela Gago-Dominguez; Susan M Gapstur; José A García-Sáenz; Mia M Gaudet; Graham G Giles; Mark S Goldberg; Anna González-Neira; Grethe I Grenaker Alnæs; Mervi Grip; Pascal Guénel; Christopher A Haiman; Per Hall; Ute Hamann; Elaine F Harkness; Bernadette A M Heemskerk-Gerritsen; Bernd Holleczek; Antoinette Hollestelle; Maartje J Hooning; Robert N Hoover; John L Hopper; Anthony Howell; Milena Jakimovska; Anna Jakubowska; Esther M John; Michael E Jones; Audrey Jung; Rudolf Kaaks; Saila Kauppila; Renske Keeman; Elza Khusnutdinova; Cari M Kitahara; Yon-Dschun Ko; Stella Koutros; Vessela N Kristensen; Ute Krüger; Katerina Kubelka-Sabit; Allison W Kurian; Kyriacos Kyriacou; Diether Lambrechts; Derrick G Lee; Annika Lindblom; Martha Linet; Jolanta Lissowska; Ana Llaneza; Wing-Yee Lo; Robert J MacInnis; Arto Mannermaa; Mehdi Manoochehri; Sara Margolin; Maria Elena Martinez; Catriona McLean; Alfons Meindl; Usha Menon; Heli Nevanlinna; William G Newman; Jesse Nodora; Kenneth Offit; Håkan Olsson; Nick Orr; Tjoung-Won Park-Simon; Alpa V Patel; Julian Peto; Guillermo Pita; Dijana Plaseska-Karanfilska; Ross Prentice; Kevin Punie; Katri Pylkäs; Paolo Radice; Gad Rennert; Atocha Romero; Thomas Rüdiger; Emmanouil Saloustros; Sarah Sampson; Dale P Sandler; Elinor J Sawyer; Rita K Schmutzler; Minouk J Schoemaker; Ben Schöttker; Mark E Sherman; Xiao-Ou Shu; Snezhana Smichkoska; Melissa C Southey; John J Spinelli; Anthony J Swerdlow; Rulla M Tamimi; William J Tapper; Jack A Taylor; Lauren R Teras; Mary Beth Terry; Diana Torres; Melissa A Troester; Celine M Vachon; Carolien H M van Deurzen; Elke M van Veen; Philippe Wagner; Clarice R Weinberg; Camilla Wendt; Jelle Wesseling; Robert Winqvist; Alicja Wolk; Xiaohong R Yang; Wei Zheng; Fergus J Couch; Jacques Simard; Peter Kraft; Douglas F Easton; Paul D P Pharoah; Marjanka K Schmidt
Journal:  Breast Cancer Res       Date:  2022-01-04       Impact factor: 8.408

8.  Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways.

Authors:  Gesche Frohwitter; Horst Buerger; Paul J VAN Diest; Eberhard Korsching; Johannes Kleinheinz; Thomas Fillies
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

9.  Radiological audit of interval breast cancers: Estimation of tumour growth rates.

Authors:  Emma G MacInnes; Stephen W Duffy; Julie A Simpson; Matthew G Wallis; Anne E Turnbull; Louise S Wilkinson; Keshthra Satchithananda; Rumana Rahim; David Dodwell; Brian V Hogan; Oleg Blyuss; Nisha Sharma
Journal:  Breast       Date:  2020-04-01       Impact factor: 4.380

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.